Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (IN-PASC)

NCT05350774 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT05350774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05350774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (IN-PASC)
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
July 10, 2023
Completion date
December 15, 2026
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microvascular thrombosis, neuroinflammation, systemic inflammation